Vinva Investment Management Ltd Buys 14,169 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Vinva Investment Management Ltd raised its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 408.4% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 17,638 shares of the company's stock after buying an additional 14,169 shares during the quarter. Vinva Investment Management Ltd's holdings in IDEXX Laboratories were worth $7,280,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in IDXX. FSA Wealth Management LLC acquired a new stake in shares of IDEXX Laboratories in the third quarter worth $25,000. Rialto Wealth Management LLC acquired a new stake in IDEXX Laboratories in the 4th quarter worth $30,000. Retirement Wealth Solutions LLC bought a new position in shares of IDEXX Laboratories during the 4th quarter worth about $31,000. Kestra Investment Management LLC acquired a new position in shares of IDEXX Laboratories during the fourth quarter valued at about $38,000. Finally, Crews Bank & Trust acquired a new position in shares of IDEXX Laboratories during the fourth quarter valued at about $41,000. 87.84% of the stock is owned by institutional investors.

IDEXX Laboratories Price Performance

Shares of IDEXX Laboratories stock traded up $0.37 during trading on Friday, reaching $420.99. The company's stock had a trading volume of 706,610 shares, compared to its average volume of 552,075. The stock has a 50-day moving average price of $437.36 and a two-hundred day moving average price of $444.94. The stock has a market capitalization of $34.12 billion, a P/E ratio of 39.46, a price-to-earnings-growth ratio of 3.41 and a beta of 1.39. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. IDEXX Laboratories, Inc. has a one year low of $398.50 and a one year high of $548.88.

Remove Ads

Insider Buying and Selling at IDEXX Laboratories

In other news, EVP George Fennell sold 9,986 shares of the stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the sale, the executive vice president now directly owns 8,176 shares of the company's stock, valued at $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director M Anne Szostak sold 3,000 shares of the business's stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the completion of the transaction, the director now owns 3,061 shares of the company's stock, valued at $1,426,242.34. This trade represents a 49.50 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 2.11% of the company's stock.

Analyst Ratings Changes

IDXX has been the topic of several research reports. Leerink Partners started coverage on IDEXX Laboratories in a research note on Monday, December 2nd. They set an "outperform" rating and a $500.00 price target on the stock. Leerink Partnrs raised IDEXX Laboratories to a "strong-buy" rating in a research report on Monday, December 2nd. Piper Sandler boosted their price target on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a report on Monday, February 10th. StockNews.com downgraded shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Saturday, March 15th. Finally, Bank of America increased their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a research note on Tuesday, February 4th. Four analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $533.75.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.